Physician profile
Augustine E Iluore
NPI 1336205442
$1,611.46
in general payments reported to CMS, 2019-2025
16 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $186 · 2021: $128 · 2022: $235 · 2023: $250 · 2024: $329 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.73 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $339.21 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $289.35 | 2019-2023 | |
| Lilly USA, LLC | $263.75 | 2019-2024 | Mounjaro, Trulicity, Amyvid |
| Amarin Pharma, INC. | $189.71 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $159.83 | 2019-2022 | |
| Dexcom, INC. | $62.15 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.52 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $47.12 | 2021-2022 | |
| Glaxosmithkline, LLC. | $46.59 | 2024 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $26.21 | 2024 | Voquezna |
| Abbvie INC. | $25.76 | 2024 | |
| Pfizer INC. | $24.84 | 2024 | |
| Galderma Laboratories, L.P. | $24.42 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $23.35 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.05 | 2025 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $18.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine Iluore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.